Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1503

Shown on this page

Current sort

Live official records

Conditions: Waste Output
Interventions: Toilet seat that measures waste output; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Medulloblastoma
Interventions: Difluoromethylornithine; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 21 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 25
States / cities: Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more

Conditions: Congenital Heart Disease (CHD)
Interventions: Umbilical Cord Clamping at ~30 seconds, Umbilical Cord Clamping at ~120 seconds, Umbilical Cord Milking; Procedure
Lead sponsor: Carl Backes, MD; Other
Eligibility: 37 Weeks to 42 Weeks
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 15 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 54
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more

Conditions: Generalized Myasthenia Gravis
Interventions: Iptacopan, Matching Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more

Conditions: Non-small Cell Lung Cancer
Interventions: Osimertinib, Selumetinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more

Conditions: Neoplasms
Interventions: Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 10 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 24
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 19 more

Conditions: Mild Cognitive Impairment, MCI
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sarcoma,Soft Tissue
Interventions: INT230-6, Eribulin, Trabectedin, Pazopanib; Drug
Lead sponsor: Intensity Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more

Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
Interventions: Afamitresgene autoleucel; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 10
States / cities: Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 7 more

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

About this Duke University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Duke University Medical Center

Filter and sort this campus

Live official records

Prototyping a Device for Automating Stool and Urine Output Tracking

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Cord Clamping Among Neonates With Congenital Heart Disease

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Neuromodulation of Memory in Aging

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

SPEARHEAD-3 Pediatric Study

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

About this Duke University Medical Center institution page